Vatreptacog Alfa (Activated)

Summary

Vatreptacog Alfa (Activated) (CHEMBL2108322) is a phase-3 clinical-stage unknown; indicated across 2 conditions including hemophilia a and hemophilia b.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Indications: 2 conditions
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2108322
Name	Vatreptacog Alfa (Activated)
Type	Unknown
Max phase	3

Also known as: NN-1731, NN1731, Vatreptacog alfa, Vatreptacog alfa (activada), Vatreptacog alfa (activated), Vatreptacog alfa (active), VATREPTACOG ALFA (ACTIVATED)

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
hemophilia A	2	MONDO:0010602	MONDO:0010602
hemophilia B	2	MONDO:0010604	MONDO:0010604

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE3	1
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01392547	PHASE3	COMPLETED	Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
NCT00486278	PHASE2	COMPLETED	Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds
NCT00822185	PHASE1	COMPLETED	Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).